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Abstract
Objective—To use electronic diaries (e-diaries) to determine whether pain, stiffness, and fatigue
continue to be common, disabling symptoms in children with juvenile idiopathic arthritis (JIA)
despite the use of aggressive treatments in contemporary medical management.
Methods—Fifty-nine children with JIA (ages 8–18 years) provided ratings of pain, stiffness, and
fatigue intensity and functional limitations using a smartphone e-diary 3 times each day for 1
month. Medication information was collected via parent report and checked for accuracy by chart
review. Descriptive analyses were conducted to determine typical symptom intensity, frequency,
and variability. Multilevel modeling was used to analyze associations between symptoms and
functional outcomes and between medication use and symptom intensity.
Results—Children reported moments of pain in 66% of e-diary entries. No children were
entirely pain-free across the reporting period. In 31% of all e-diary entries the visual analog scale
score for pain was >40 (high pain intensity), with 86% of children reporting a high level of pain at
least once during the study period. The mean ratings of pain, stiffness, and fatigue intensity were
in the mild-to-moderate range. Medication class was not a reliable predictor of differences in
symptom intensity, even though 79% of children were prescribed a disease-modifying
antirheumatic drug and 47% were prescribed a biologic agent. Moments of higher pain intensity
and higher stiffness intensity were each uniquely predictive of higher concurrent functional
limitations.
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Conclusion—Self-reported pain, stiffness, and fatigue continue to be common in children with
JIA, despite contemporary advances in treatment strategies, including use of biologic agents.
These findings are surprisingly consistent with previous results from research using daily paper
diaries in the pre-biologics era. There remains a pressing and ongoing need to optimize pain and
symptom management in JIA.
Juvenile idiopathic arthritis (JIA) is characterized by periods of disease flare that are often
accompanied by pain, fatigue, debilitating morning stiffness, and difficulty performing
activities at home and at school. Previous research has consistently demonstrated that pain is
a common, clinically significant symptom in children with JIA, with many children
experiencing persistent pain despite stable disease activity (1–7). Our previous studies found
that children reported having pain and stiffness on 70% of days, with 25% of children with
polyarticular arthritis reporting pain intensity in the highest range of the pain scales (8). The
presence of pain substantially impacts the lives of children with JIA, reducing performance
of routine physical tasks and participation in social or school activities (8–11). Greater
fluctuations in pain intensity have been associated with lower quality of life in children with
JIA (12), and pain was an important determinant of physical and psychosocial well-being in
a cross-sectional study of 3,167 children with JIA from 30 countries (6).
Despite the strength of evidence supporting the persistence of pain in children with JIA, the
majority of this research was conducted prior to recent advances in pharmacotherapy. In our
original diary study (8), which highlighted the daily frequency and intensity of JIA pain,
73% of children were treated with methotrexate and only 17% with a biologic agent. Since
that time, clinical trials, consensus treatment plans, and treatment guidelines all have called
for more aggressive JIA treatment involving utilization of biologic agents (13–15). Although
pain has not been studied as an independent measure of drug efficacy and has been
demonstrated to have a weak relationship with indices of disease activity (1,16–19), it has
been identified as a quality indicator of JIA care (20) and is important to investigate in the
context of treatment advances.
Technology has also advanced beyond paper diary methods for measuring pain and
functioning in the context of a child’s daily life. Specifically, smartphones (phones with
advanced computing capability) afford ease in obtaining repeated measures of pain within
and across days and improves the quality of the self-reported data through prompts and
automatic time-stamping (21–23). The use of mobile devices for capturing self-reported data
via electronic diaries (e-diaries) has been validated in children with arthritis and effectively
captures current symptom reports (24–27).
In the present study, we assessed the pain experience of children with JIA being treated with
current pharmacotherapies in the contemporary biologics era. Specifically, we examined
temporal relationships between pain, daily symptoms, and daily functional outcomes in
children with JIA, using self-reported data from e-diaries completed 3 times daily. The first
aim was to describe current patterns of pain and other symptoms, including frequency and
intensity, in children with JIA. The second aim was to describe the associations between use
of different medication classes and pain and symptom intensity. Finally, the third aim was to
determine whether pain alone or in combination with stiffness and fatigue could be used to
Bromberg et al. Page 2






















predict functional limitations in children with JIA. We hypothesized that a combination of




Study participants were recruited between August 2010 and May 2011 from a pediatric
rheumatology clinic at an academic medical center in the southeastern United States.
Children between the ages of 8 and 18 years who were diagnosed as having JIA were
recruited for the study if they reported experiencing joint pain within the 6 months prior to
study recruitment. Children were excluded if they were 1) diagnosed as having a comorbid
disorder affecting their current pain and functioning (e.g., mood disorder, fibromyalgia,
pervasive developmental disorder), 2) known to have significant cognitive impairment or
illiteracy that would limit understanding of study measures, 3) non-English speaking, 4)
physically unable to complete the e-diaries, or 5) not currently attending school (e.g., not
enrolled or on academic breaks).
Ninety-three families were approached for recruitment into the study. Of those approached,
19 (20%) declined to participate due to time constraints on the day of the clinic visit, lack of
interest, or self-perceived inability to complete the study activities once enrolled. Of the 74
families who consented to participate, additional screening identified 3 families as ineligible
based on the exclusion criteria. Four participants withdrew prior to study completion due to
time constraints or difficulties with wireless signal reliability (for transmitting daily diary
responses). Eight additional participants were removed from the study by the principal
investigator due to persistent lack of consistency in diary completion. There were no
differences in sex, age, or disease activity between the group of children who completed the
study and those who did not complete the study.
The final sample comprised 59 children (44 girls) ages 8–18 years (mean ± SD age 13.30 ±
2.78 years). Those children who had at least 25 repeated measurements were included in the
data analysis, which is an adequate number for obtaining reliable parameter estimates in
hierarchical linear analyses (28,29). The majority of participants self-identified their race as
Caucasian (73%), followed by black or African American (11%) and mixed racial
background (5%), reflecting the race and ethnicity of the clinic population. Three patients
(6%) self-identified as Hispanic. The school grade ranged from third grade to twelfth grade,
with 93% of children attending public schools and the remainder attending private schools.
No children in the study were being homeschooled. Of the sample, 11% were classified by
the pediatric rheumatologist as having minimal disease activity, while 42%, 43%, and 4%
were classified as having mild, moderate, and severe disease activity, respectively. The
primary caregiver was predominantly the biologic mother for most of the children (86%).
The majority of children in the sample had been prescribed disease-modifying antirheumatic
drugs (DMARDs), as determined by chart review (79%) or based on caregiver report (54%).
Biologic agents were the next most commonly prescribed medication, as verified by chart
review (47%) or by caregiver report (32%). In addition, caregiver reports indicated that 32%
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of children were being treated with nonsteroidal antiinflammatory drugs (NSAIDs), while
chart review revealed that 38% of children had been prescribed routine NSAIDs, with 7%
taking NSAIDs as needed. Few children in this sample were taking opioids (<3%).
Procedure
Patients scheduled for evaluation in the pediatric rheumatology clinic were prescreened by a
research assistant and reviewed by the study rheumatologist (LES). A study information
letter was sent to the families of potential participants ~1 week before a scheduled
appointment. During the baseline study visit, interested families provided written informed
consent (and written assent for children ages ≥12 years) according to local Institutional
Review Board requirements. Enrolled children and caregivers independently completed
computerized baseline self-report measures. The children were then trained to use
customized e-diaries on a smartphone (T-Mobil Dash) and completed a sample entry while
being supervised by a research assistant. Information on typical times for starting school,
coming home from school, dinner, and bedtime was gathered from each family in order to
program audible alerts to cue the child to complete a diary entry 3 times during the day
(morning, afternoon, and evening). Children were not cued during school hours, because of
school policies pertaining to phone use.
After completing the baseline assessments and e-diary training, participants took home the
smartphones and a printed instruction manual. Participants were instructed to complete 3
surveys per day at the cued times, for a total of 28 days. Data were automatically uploaded
from the phone to a password-secured internet server through the phone’s wireless data plan.
Families received standardized, weekly calls from the research assistant to promote e-diary
completion and address barriers to e-diary completion. At the end of the diary period,
smartphones were returned in a prepaid mailer given to families at enrollment. Children
were reimbursed for participation based on number of completed e-diary entries ($0.25/
completed entry, with a $0.50 bonus for completing all entries on a given day and a $1.25
bonus for completing a full week’s worth of diary entries, for a possible total of $10.00).
E-diary measures
Pain intensity—Current pain intensity was quantified using a horizontal visual analog
scale (VAS) with the anchors of “no pain” to “worst possible pain.” A 50-mm horizontal
line (one-half filled in with blue color) was shown on the smartphone screen, and children
were asked to move the filled-in portion of the line to represent their current level of pain.
Children received a warning message reminding them to select their current pain level if
they did not move the line from the original starting point. Scores were transformed to a 0–
100 scale to be consistent with the typical metric for VAS scoring. Consistent with methods
used in our previous paper diary study (8), pain intensity scores of ≥3 (of 100) were used to
derive the number of days children experienced pain (pain frequency). This electronic VAS
has been previously validated for the measurement of pain intensity in children and
adolescents with JIA (25).
Pain location—Respondents were shown an image of a skeleton with numbered circles at
major body areas (e.g., head, hands, arms, hip and knee, feet) and asked to indicate where
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the pain was currently occurring. This image was adapted from paper versions of a pain
body map used previously in children with JIA (8). A zoomed-in image of painful areas of
the body was then provided and children were asked to identify specific painful joints within
each body area. The sum total of painful areas (among 7 body areas) was used for the
analyses.
Pain duration—The duration of pain was quantified using a 4-point ordinal scale.
Children were asked to indicate the duration of current pain, ranging from “a few minutes”
to “more than 4 hours.” A “not applicable” option also was provided.
Pain unpleasantness—Children reported the extent to which the pain was bothering
them by moving the filled portion of a 50-mm horizontal line (one-half filled in with blue
color) displayed on the smartphone screen, with the anchors of “not bothering me at all” to
“bothering me a lot.” Scores were transformed to a 0–100 scale.
Functional limitations—Social, academic, and physical functional limitations were
assessed using questions derived from the Activity Scale for Kids (30) and the Child
Activity Limitations Questionnaire (31). Children were asked to report the extent of
difficulty they were having with each of 8 items during each daily time interval, using a 4-
point scale ranging from “not very difficult” to “extremely difficult.” The items varied in the
morning, afternoon, and evening assessments based on the activities likely to occur at those
times. For example, a question about difficulties putting on clothes was asked in the
morning assessment only, whereas questions about social or school activity limitations were
asked at the afternoon and evening times. An additive summary score was calculated for
each time point, with higher scores indicating greater overall functional limitations.
Stiffness and fatigue intensity—The intensity of current stiffness and intensity of
current fatigue were quantified in a manner similar to that used to quantify pain intensity,
using a horizontal VAS with the anchors of “no stiffness” to “a lot of stiffness” for
evaluation of stiffness intensity and the anchors of “not at all tired” to “very tired” for
evaluation of fatigue intensity. A 50-mm horizontal line (one-half filled in with blue color)
was shown on the smartphone screen, and children were asked to move the filled-in portion
of the line to represent their current level of stiffness or fatigue. Scores were transformed to
a 0–100 scale.
Stiffness and fatigue duration—The duration of current stiffness and fatigue was
quantified using a 4-point ordinal scale, ranging from “a few minutes” to “more than 4
hours.” A “not applicable” option also was provided.
Baseline measures
Joint count and disease activity—Each participant’s pediatric rheumatologist
completed an active joint count for each child, consisting of the number of swollen and
tender joints and the number of joints in which range of motion was limited (32). In
addition, the child’s disease activity was rated on a 0–3 scale, ranging from minimal (score
of 0) to severe (score of 3).
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Medications—Information on current medications was gathered at the time of the initial
study visit. Both caregiver-reported medications and medication lists from chart review were
used in the data analyses to differentiate between the scheduled use of prescription NSAIDs
and the as-needed use of NSAIDs. Caregiver-reported medications were classified into 1 of
5 categories for analyses: NSAIDs or acetaminophen, DMARDs (methotrexate,
lenalidomide), opioids (oxycodone, methadone), biologics (etanercept, infliximab,
adalimumab, abatacept, anakinra, and rituximab), and vitamin D and/or calcium.
Medications ascertained from chart review were classified similarly, except for the
differentiation between scheduled and as-needed NSAIDs.
Statistical analysis
For the first aim of the present study, to describe patterns of pain and other symptoms in
patients with JIA, descriptive statistics (expressed as the mean ± SD) were used to
summarize typical levels and variability of symptom intensity and symptom duration within
and across days. The proportion of days in pain and proportion of moments with high pain
intensity (VAS score >40 of 100) were also calculated. A series of hierarchical multilevel
models were used to evaluate the extent to which symptoms were associated with
medication use and functional limitations. Multilevel models account for the nesting of
observations (multiple measurements within each child) (33,34). Multilevel analyses were
specified using the SAS Mixed procedure program (35). A serial autocorrelation residual
variance structure was applied to all models to account for the fact that responses obtained
closer together in time are more similar than those obtained further apart.
For models evaluating the extent to which average symptom levels differed as a function of
medication class, all classes of medication were entered simultaneously as predictors, and
physician-reported disease activity was specified as a covariate. For models evaluating the
relationship between symptoms (pain, fatigue, and stiffness) and functional limitations, age
and physician-rated disease activity were included as covariates, and symptom intensity
values were added in a hierarchical approach in order to identify the unique effect of each
symptom on functional limitations. In these models, intensity values for pain, fatigue, and
stiffness were centered such that a child’s mean symptom intensity score (on 100-mm VAS)
was entered in the models; this permitted determination of the extent to which deviations
from a child’s average symptom intensity at a given moment is associated with increased or
decreased functional limitations at that same moment.
RESULTS
Descriptive statistics
Children in the study completed a total of 3,258 e-diary entries. This represents a 66%
completion rate, which is similar to that in our e-diary pilot study (26). Children reported
experiencing pain (VAS score ≥3 of 100) in 66% of all moments. Across all days, the
children’s endorsed levels of pain intensity and pain unpleasantness were similar (r = 0.91, P
< 0.01), suggesting that the measures captured a similar aspect of the pain experience. The
average score for stiffness intensity was 24 ± 25 and fatigue intensity was 43 ± 28 (mean ±
SD on 100-mm VAS) in all children across all moments.
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Children reported having pain (VAS score ≥3 of 100) on 72% of all diary days, and the
mean ± SD number of days of self-reported pain during the study was 18.8 ± 8.9. No
children were entirely pain-free across the reporting period, and in individual children, the
number of pain days during the study period ranged from 1 to 28. On any given pain day,
the mean ± SD pain intensity score was 36 ± 23, stiffness intensity score was 33 ± 24, and
fatigue intensity score was 49 ± 25. In 31% of all e-diary entries, children endorsed the level
of pain as being “high pain” (pain intensity score of >40 on 100-mm VAS, as defined in
prior studies [1,8]). The majority of children (n = 50 [86%]) reported experiencing high pain
at some point during the study period. The mean pain intensity score fell within the high
range (>40 of 100) for a subgroup of children (n = 13 [22%]). When children experienced
pain, they most often reported a pain duration of >4 hours. In contrast, at times when
children reported experiencing stiffness or fatigue, they reported a duration of a few
minutes.
As shown in Table 1, the mean pain intensity ratings across the morning, afternoon, and
evening entries were not significantly different. However, as expected, the mean stiffness
intensity score for children in this study was highest in the morning. Children experienced
the highest intensity of fatigue in the evening and lowest intensity of fatigue in the
afternoon. In comparison with the morning ratings of fatigue, the evening fatigue intensity
was significantly higher and afternoon fatigue intensity was significantly lower, across all
children and all e-diary entries.
There were significant correlations between all daily symptoms and functional limitations
(Table 2). The correlations between pain and other daily symptoms or functional limitations
spanned from medium (e.g., r = 0.37, P < 0.01 for correlation with number of painful joints)
to large (e.g., r = 0.73, P < 0.01 for correlation with stiffness intensity). These findings
supported our observations from the analyses of temporal associations among the factors.
Models testing the effects of medication on symp-toms
There was a consistent finding that the intensity of pain, stiffness, or fatigue did not reliably
vary as a function of medication class (neither those verified by chart review nor those
reported by the parent). For example, children prescribed biologic drugs had pain intensity
scores comparable with those of children who were not prescribed biologic drugs (t[47] =
−1.25, P > 0.05). The one exception to this pattern of findings was in children receiving a
regular regimen of NSAIDs.
Children who were regularly scheduled to take NSAIDs had significantly lower fatigue
intensity scores compared with children who were not taking NSAIDs (t[47] = −2.18, P <
0.05). In summary, when we based our analysis on whether or not a child had been
prescribed DMARDs or biologic agents to manage JIA, we did not detect any differences in
the symptom intensities reported in the e-diaries.
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Hierarchical models testing the effects of momentary symptom intensity on functional
limitations
As shown in Table 3, the association of disease activity with functional limitations was
significant, indicating that children with more severe disease could be expected to
experience higher functional limitations. Age was not a predictor of functional limitations.
The intercept for the model indicates that the expected value of functional limitations was
3.68 for a child at the average age and disease activity of the sample.
Pain intensity at any given moment was a significant predictor of functional limitations;
during times when children had higher than their usual pain intensity, they could be
expected to have greater functional limitations (t[3,040] = 19.76, P < 0.0001). The number
of painful body locations reported at any given time was a predictor of functional limitations
at that time, above and beyond the effects of pain intensity (t[3,039] = 8.44, P < 0.0001).
This finding indicates that it was important to consider not only pain intensity but also the
number of painful areas of the body when predicting how well a child might function at any
given time.
In addition, the intensity of stiffness at any given time was a predictor of functional
limitations at that time, above and beyond the effects of disease activity, pain intensity, and
painful locations (t[3,038] = 2.60,P < 0.05). Children who typically experienced more
stiffness also had greater functional limitation scores (t[49] = 3.36, P < 0.05). In contrast,
fatigue experienced at any time was not predictive of functional limitations at that time,
when analyses were controlled for disease activity, pain, number of painful areas, and
stiffness (t[3,037] = − 1.71, P = 0.09).
DISCUSSION
The results of this study indicate that pain continues to be a significant concern for children
with JIA, occurring frequently and associated with significant functional difficulties. These
findings regarding pain intensity and frequency are remarkably consistent with our previous
study findings using paper diaries (8), despite the current advances in treatments for JIA and
the large number of children in this study who were prescribed biologic agents relative to
that in the previous sample. Children also reported high levels of fatigue, particularly on
pain days, and there were moderate correlations between fatigue, pain, and stiffness. When
added as a final predictor in models containing demographic and other daily symptoms,
fatigue intensity did not account for any additional variance in functional limitations, despite
the high levels of fatigue reported by the children on a daily basis.
An important contribution of this study was the examination of daily patterns of pain and
symptoms using technologically advanced data collection methods. E-diaries allowed
examination of differences in the children’s reported symptoms across mornings, afternoons,
and evenings. Findings indicated that, on average, stiffness intensity was highest during the
morning, fatigue intensity was highest during the evening, and pain intensity was similar
across time periods. The use of repeated measures of momentary pain and other symptoms
via e-diaries offers many advantages, such as preventing backfilling and the ability to
examine patterns of associations between symptoms and behaviors as they occur.
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Using e-diaries, we were able to examine ways in which disease activity and current
medication class might be used to predict symptom intensity reports. In analyses controlled
for the level of disease activity, we failed to detect significant differences in the children’s
daily symptoms based on prescribed medication class. The only exception was a significant
difference in fatigue intensity related to the scheduled use of NSAIDs; children taking
scheduled NSAIDs had lower fatigue intensity ratings than those who were not taking
scheduled NSAIDs. The failure to detect consistent differences in the daily symptom report
based on medication class is notable, particularly given that many children in this study were
treated with biologic drugs. Children with JIA often are prescribed medications from a
combination of classes, and the method of analysis did not consider clusters of medications
or prescribing patterns, due to concerns regarding loss of statistical power.
Although these results are consistent with recent findings (36), it is possible that other
individual differences or moderating factors (e.g., stress, disease duration, mood) might have
influenced daily symptoms; none of these were controlled for in our analyses. Nevertheless,
these results raise new questions about the effectiveness of contemporary aggressive therapy
in preventing or limiting disease symptoms. Moreover, the severity of disease activity may
not be as well controlled as is often presumed by health care providers, when disease
activity is determined solely on the basis of physical examination and laboratory assessment.
Persistent pain may also be attributable to changes in pain processing in the central nervous
system (central sensitization) that remain after resolution of the inflammatory component of
the disease, and current therapies do not target this aspect of pain.
Our study also investigated the influence of pain and other symptoms on functioning in
children with JIA. We hypothesized that a combination of more intense pain and other
symptoms at a given time would be a predictor of higher functional limitations at that time.
As expected, pain intensity was a predictor of concurrent functional limitations. Individual
variations in stiffness intensity were also predictive of functional limitations, beyond the
influence of pain intensity and disease activity. However, momentary fatigue intensity was
not predictive of functional limitations, despite the high level of fatigue reported by children
in the study. It is possible that children are more willing or able to tolerate fatigue and it
does not impact activity involvement, or perhaps fatigue occurs as a delayed effect of
activity involvement. Our measurement of fatigue was limited to a single item on each e-
diary inquiring about tiredness, which likely did not fully capture the nuances of fatigue as a
disease symptom. Additionally, a common symptom-reporting method was used (the VAS),
increasing the potential influence of method invariance on children’s reporting practices,
and possibly contributing to the detected results (37). Further research into the cause, nature,
and role of daily fatigue is needed, as this is a symptom not previously well studied in JIA
and not currently part of routine treatment response criteria. Taken together, these findings
indicate that it is important for health care providers to consider children’s overall symptom
report in the context of functional limitations; assessing and treating pain intensity alone
may not fully explain or alleviate children’s functional impairment.
Routine assessment and treatment of pain, stiffness, and fatigue intensity should be part of
the clinical care regimen, along with the assessment of treatment efficacy in clinical trials
for children with JIA. There are brief tools available for capturing symptom reports at clinic
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visits (38,39) in order to guide pain management approaches and track treatment outcomes.
In addition, pain and disease symptoms should be examined independently of other disease
activity measures in clinical trials. Currently, little is known about the direct effect of
specific medications on pain and other disease symptoms. While our study did not show a
difference between classes of medication and the symptoms report, we aggregated all
biologic agents together. It may be that specific biologic agents are better than others at
treating specific disease symptoms or that future medications may prove to be more
successful than those currently available for treating pain, fatigue, and stiffness.
Additionally, it is important to note that pain and other symptoms appear to be related and
that interventions addressing one symptom (e.g., pain) may promote reductions in other
symptoms and improve functioning.
Our findings indicating that the prescribed class of medication had little effect on daily
symptom intensity, in conjunction with existing evidence showing that disease factors only
partially account for changes in pain intensity, once again highlight the pressing and often
overlooked need to incorporate nonpharmacologic interventions into the care of children
with JIA. Cognitive behavioral therapy, including pain coping and self-management, is an
empirically supported treatment targeting pain and associated health outcomes in children
with JIA (40,41) and other childhood chronic illnesses, such as sickle cell disease (42),
functional abdominal pain (43), and headache (44). However, non-pharmacologic services
are not widely available and, historically, have not been covered by insurance. Access is
often limited to financially secure families served in major academic medical centers with
comprehensive mental health resources. Therefore, alternative methods of service delivery
are needed for broader dissemination of pain-coping skills training to children with JIA.
The increased use of e-health tools is a promising avenue for service delivery. This study
and others have shown that children with JIA can easily use handheld devices to track
symptoms and behaviors (24–27). Most children and adolescents in the United States own,
or have frequent access to, cellular phones, often smart-phones. As of February 2012, nearly
one-half (46%) of adults in the United States were smartphone users (45). Smartphones offer
a promising method for delivering a variety of medical and psychosocial pain and arthritis
treatments. Smartphone applications can also prospec-tively assess treatment outcomes in
the child’s typical environment, rather than depending on a return clinic visit for
posttreatment assessment. Smartphones can capture in-the-moment reports, and provide
immediate feedback and recommendations targeting symptom reduction and improved
functioning. For example, smart-phone applications could teach children in-the-moment
coping techniques and prompt practice in response to current symptoms. Recruitment and
retention may be promoted by incorporating participant feedback during development (24),
and by implementing brief interventions with a short reporting period coupled with the
motivation of potential direct benefits from participation. We are currently piloting a
smartphone application to test the feasibility and effectiveness of a mobile self-management
program for improving the health outcomes of children with JIA.
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Table 1
Aggregate patterns of symptoms across the day
Time of e-diary entry*
Morning Afternoon Evening F
Pain intensity score 26.6 26.0 26.4 0.153
Stiffness intensity score 26.5†‡ 23.6‡§ 23.5†§ 4.65¶
Fatigue intensity score 42.6†‡ 36.8§ 48.1§ 37.98#
No. of painful joints 4.2 3.9 4.0 0.377
No. of painful body areas 2.0 2.0 2.1 0.493
*
Values are the mean.
†
Significantly different versus afternoon.
‡
Significantly different versus evening.
§
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Table 3
Hierarchical multilevel models assessing predictors of functional limitations*
Level, predictor B t
Step 2
  Age −0.16 −0.89
  Disease activity 2.08 3.09†
Step 3
  Pain intensity
    Within-child 0.11 19.76‡
    Between-child 0.12 6.94‡
Step 4
  No. of painful body areas
    Within-child 0.99 8.44‡
    Between-child 0.004 0.01
Step 5
  Stiffness intensity
    Within-child 0.019 2.60†
    Between-child 0.10 3.36†
Step 6
  Fatigue intensity
    Within-child −0.01 −1.71
    Between-child 0.008 0.16
*
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